Live In Play®
Updated: 14-May-26 16:08 ET
ZYME:  Zymeworks announces its Board of Directors has authorized a share repurchase program under which the Company may repurchase up to $125.0 mln of its outstanding common stock, par value $0.00001 per share  (23.96 -0.61)
  • Concurrently, Zymeworks has terminated its existing 2025 share repurchase program under which the Company has repurchased 4,197,553 million shares of common stock for $102.3 million, representing an average purchase price of $24.36 per common share.
  • As of May 13, 2026, the Company had approximately 73.0 million outstanding common shares.
  • The program will be funded through the Company's strong balance sheet, leveraging its financial capacity to repurchase shares.
Cookies are essential for making our site work. By using our site, you consent to the use of these cookies. Read our cookie policy to learn more.
Send
Chat Icon